Roche says breast cancer late-stage study met primary endpoint [Reuters]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Reuters
Roche says breast cancer late-stage study met primary endpoint | Reuters 1 Min Read ZURICH, Oct 15 (Reuters) - Roche said its Kadcyla, an antibody drug to treat breast cancer, reduced the risk of the disease recurring in patients with HER2-positive early breast cancer in a late-stage study. The phase III Katherine study met its primary endpoint, showing Kadcyla as a single agent significantly reduced the risk of disease recurrence or death compared to Herceptin as an adjuvant treatment in people with HER2-positive early breast cancer, the Swiss company said in a statement on Monday. Reporting by Silke Koltrowitz; editing by Thomas Seythal All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. © 2018 Reuters. All Rights Reserved. Roche says breast cancer late-stage study met primary endpoint ZURICH, Oct 15 (Reuters) - Roche said its Kadcyla, an antibody drug to treat breast cancer, reduced the risk of the disease recurring in patients
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- AI for drug discovery draws a $1 billion launch—and a lot of hope [Yahoo! Finance]Yahoo! Finance
- AI for drug discovery draws a $1 billion launch—and a lot of hope [Fortune]Fortune
- Xaira, an AI drug discovery startup, launches with a massive $1B, says it's ‘ready' to start developing drugs [TechCrunch]TechCrunch
- Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales [Yahoo! Finance]Yahoo! Finance
- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance